Bevacizumab antibody | AbD16748_hIgG1
A microtiter plate was coated overnight with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, Human Anti-Bevacizumab:HRP Antibody, clone AbD16748_hIgG1 (HCA184P) was added at a concentration of 2 μg/ml in HISPEC Assay Diluent (BUF049A). Detection was performed using QuantaBlu Fluorogenic Peroxidase Substrate.
A microtiter plate was coated overnight with recombinant human VEGF protein at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of bevacizumab (0.3 μg/ml) plus increasing concentrations of Human Anti-Bevacizumab Antibody, clone AbD16748 (HCA184). Free bevacizumab, still capable of binding to the human VEGF coated plate was detected using Mouse Anti-Human IgG (Fc) CH2 Domain:HRP (MCA647P) in HISPEC Assay Diluent (BUF049A) followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
A microtiter plate was coated overnight with Human Anti-Bevacizumab Antibody, clone AbD17976 (HCA182) at a concentration of 1 µg/ml. After washing and blocking with PBST+5% BSA, 10% Human Serum was added spiked with increasing concentrations of bevacizumab. Detection was performed by Human Anti-Bevacizumab:HRP Antibody, clone AbD16748_hIgG1 (HCA184P) at a concentration of 4 µg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate.
A microtiter plate was coated overnight with bevacizumab at a concentration of 0.5 µg/ml. After washing and blocking with PBST+5% BSA, Human Anti-Bevacizumab Antibody clone AbD16748_hIgG1 (HCA184) in PBST + 10% Human Serum was added. Detection was performed using HRP conjugated bevacizumab at a concentration of 2 µg/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate.
Human anti Bevacizumab:HRP
Anti-bevacizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format; it is suitable for bioanalytical method development. It can be used as the detection antibody in a PK bridging ELISA with HCA182, and as a reference standard in an ADA bridging ELISA.
Human anti Bevacizumab
Anti-bevacizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format; it is suitable for bioanalytical method development. It can be used as the detection antibody in a PK bridging ELISA with HCA182, and as a reference standard in an ADA bridging ELISA.
- Product Type
- Monoclonal Antibody
- Clone
- AbD16748_hIgG1
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| HCA184P | E | 0.1 mg |
|
|
| HCA184 | E | 0.1 mg |
|
|
| HCA184G | E | 1 mg |
|
Human Anti-Bevacizumab Antibody, clone AbD16748_IgG1 is a paratope-specific, recombinant anti-idiotypic antibody that specifically recognizes the humanized monoclonal antibody drug bevacizumab and inhibits the binding of the drug to its target, vascular endothelial growth factor A (VEGF-A). The antibody can be used to measure the levels of bevacizumab and biosimilars in serum from patients.
A pair of anti-bevacizumab antibodies can be used to develop a pharmacokinetic (PK) bridging ELISA to measure free drug. This antibody is recommended as the detection antibody, paired with Anti-Bevacizumab Antibody in monovalent Fab format, clone AbD17976 (HCA182) as the capture antibody.
Bevacizumab (reference product branded as Avastin) is a humanized monoclonal antibody (IgG1/kappa) that inhibits angiogenesis by binding to VEGF-A. VEGF-A is a potent stimulator of angiogenesis of both normal and cancerous cells, and acts as a regulator of vasculogenesis. Bevacizumab is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.
View a summary of all Anti-Bevacizumab Antibodies.
A pair of anti-bevacizumab antibodies can be used to develop a pharmacokinetic (PK) bridging ELISA to measure free drug. This antibody is recommended as the detection antibody, paired with Anti-Bevacizumab Antibody in monovalent Fab format, clone AbD17976 (HCA182) as the capture antibody.
Bevacizumab (reference product branded as Avastin) is a humanized monoclonal antibody (IgG1/kappa) that inhibits angiogenesis by binding to VEGF-A. VEGF-A is a potent stimulator of angiogenesis of both normal and cancerous cells, and acts as a regulator of vasculogenesis. Bevacizumab is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian.
View a summary of all Anti-Bevacizumab Antibodies.
Product Details
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line.
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline.
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Bevacizumab
- Purity
- 97.8% (capillary electrophoresis, reducing conditions).
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD=2.1nM by real time, label-free molecular interaction analysis on immobilized Bevacizumab.
- Approx. Protein Concentrations
- Total protein concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Pack Size: 0.1 mgAntibody concentration 0.5 mg/mlPack Size: 1 mgAntibody concentration 1.0 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch.
- Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Avastin is a trademark of Genentech, Inc. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Bevacizumab antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA | |||
| ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA or as a detection reagent in a sandwich ELISA together with HCA182 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug - ELISA
- This product may be used in a direct ELISA or as a detection reagent in a sandwich ELISA, when conjugated to HRP, together with HCA182 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
This antibody is fully human and can be used as a reference standard in an ADA assay.
Protocol: ADA bridging ELISA
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Human anti Bevacizumab | HCA182 | E | 0.1 mg |
|
|
| Human anti Bevacizumab | HCA182 | E | 0.1 mg |
|
|
| Human anti Bevacizumab | HCA185 | E | 0.1 mg |
|
|
| LYNX Rapid HRP Antibody Conjugation Kit | LNK001P | CJ | 1 Conjugation For 400µg Antibody |
Product Specific References
References for Bevacizumab antibody
-
Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
US Patent Application US20170315118A1
